Molecular biology laboratories + Life science laboratories
Molecular biology laboratories + Life science laboratories
By combining deep technical expertise with a commitment to addressing drug resistance, Amaterasu Life Sciences advances patient care through next-generation drug-delivery technologies.
SiDMI exemplifies this approach—redefining malaria treatment by addressing a critical unmet need for therapies that are both effective and patient-friendly. As malaria continues to pose a major global health challenge, SiDMI offers a transformative solution that improves adherence and outcomes while maximising the value of existing medicines. Its development highlights the essential role of innovation in reshaping treatment paradigms and driving progress in global healthcare
Malaria continues to cause millions of illnesses and hundreds of thousands of deaths each year, particularly in low-resource, high-burden regions. Current artemisinin-based therapies require multiple oral doses over several days or standalone injectable treatments, often resulting in poor adherence, incomplete cure, and increasing artemisinin resistance. Patients in vulnerable settings frequently miss doses or discontinue treatment due to side effects and limited access, leading to relapse, complications, and continued disease transmission.
SiDMI is a first-in-class, single-dose intramuscular injection designed to deliver a complete course of Artemisinin Combination Therapy (artemether–lumefantrine) using Amaterasu’s proprietary SMEDDS-based, in-situ gelling depot technology. Following injection, the liquid formulation rapidly converts into a gel within the muscle, creating a depot that releases both drugs in a controlled, bio-enhanced manner—achieving curative exposure from a single dose.
Patent status:
• India: Patent granted for the liquid injectable composition and depot technology.
• USA: Patent granted for the same composition and platform.
Incomplete malaria treatment remains a major driver of relapse, complications, and drug resistance. In high-burden, low-resource settings, multi-day oral regimens are difficult to complete, particularly among vulnerable populations.
By delivering a full curative course in a single intramuscular dose, SiDMI has the potential to transform malaria care—ensuring adherence, reducing disease transmission, and improving outcomes where healthcare access is limited. This approach supports more reliable treatment, lowers the risk of resistance development, and helps protect both individual patients and public health at scale.
• Ensures complete treatment compliance with a single-dose injection
• Provides a potentially lifesaving option for high-risk populations, including children and pregnant women
• Helps reduce the risk of drug resistance, relapse, and treatment-related complications
SiDMI is designed to serve patients in malaria-endemic regions, with particular impact for children and adults who have limited access to continuous healthcare. It also supports public health programs, governments, and NGOs seeking scalable, field-ready solutions that improve treatment adherence and deliver better clinical outcomes.
The SiDMI platform, formulation, and preclinical pharmacokinetic and pharmacodynamic packages have been successfully established, demonstrating strong efficacy and safety in animal models. GMP-compatible manufacturing processes have been developed to support scale-up. The innovation has also received industry recognition, including acknowledgement at major forums such as the CPHI Pharma Awards, underscoring its potential impact in global health.
SiDMI is advancing toward clinical development and is actively seeking strategic partnerships to accelerate its path to patients. Amaterasu welcomes collaboration with pharmaceutical partners, global health organizations, funding agencies, and public health institutions to support clinical trials, regulatory development, manufacturing scale-up, and deployment in malaria-endemic regions.
Through shared expertise and aligned commitment, these partnerships can help translate a promising innovation into a scalable, accessible solution capable of delivering meaningful impact in global malaria control and elimination efforts.
SiDMI is being developed in collaboration with:
for bringing deep formulation and drug delivery expertise.
for its funding, validation and translational support
as its incubation partner
as development partner bringing in its manufacturing, regulatory and business development expertise.